CMC Blog

Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer
June 22nd, 2017

June 22, 2017 – Vancouver, BC – Canabo Medical Inc. (TSXV:CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its second clinic in Nova Scotia for a total of 22 clinics and partner clinics nation-wide. The new clinic, located in Wolfville, Nova Scotia is now accepting referrals. As the second clinic for the province of Nova Scotia, this opening represents a broadening of Canabo’s national clinic footprint.

As previously discussed on June 5 in the Company’s Corporate Update, the clinic reports new patient volumes continue at record levels.
Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “As explained in our June 5th Corporate Update we reiterate, there was no fundamental reason for the sharp decline in our share price during May. The Company’s operating fundamentals and growth trajectory remain strong.”

Canabo also announces today the appointment of Mr. Garry Stewart as Chief Financial Officer.  

Mr. Stewart is a Chartered Professional Accountant who brings over 25 years of professional experience to the role. Prior to joining Canabo, Mr. Stewart served as CFO, Vice President Finance at TAR Investments Ltd., including Datarite Ltd. and Atlantic Business Interiors Ltd.  

Mr. Stewart replaces Mr. Rob Randall as Chief Financial Officer. Mr. Randall is leaving Canabo to focus on his other CFO roles but will continue to support and assist Mr. Stewart during the transition. John Philpott, President & CEO of Canabo, commented “I would like to thank Rob for his service to Canabo. He played a key role in the RTO transaction as well as the growth of the business. We wish him well in his future endeavours.”

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information, please contact:
Ms. Bianca Müller
Telephone: +1-902-334-1700 Email: media@cmclinic.ca
www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release

Canabo’s Executive Chairman Provides Corporate Update on Company’s First Six Months as a Public Company
June 5th, 2017

June 5, 2017 – Vancouver, BC – Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. (TSXV:CMM) (OTCQB:CAMDF) (“Canabo” or the “Company”) is pleased to provide a corporate update on the Company’s first six months since listing on the TSX-V Exchange. 

Dr. Smith outlined a number of key accomplishments that support the Company’s business focus toward being the dominant clinic network, research provider and data analytics source in the cannabis industry.

  • Canabo treatments are now available in 16 clinic locations nationally, up from 10 locations at the time of listing. Canabo is also expanding its clinic footprint through agreements to open up to 30 partner clinic locations across the country. 
  • The Company has cash on hand of approximately $8.5 million or $0.22 per share.
  • Over the past six months, Canabo has completed 14,000 physician/patient appointments including 5,500 with new, first visit patients.
  • A financing of $8.4 million was completed at a price of $1.40 per share.  
  • Canabo entered into an R&D Agreement with Terra Life Sciences Inc. to develop condition specific treatments. The agreement is expected to result in both near-term research study revenue and ultimately licensing revenue from any new treatments developed.
  • Canabo released a milestone study on benzodiazepine use, showing a marked drop in use among Canadian patients using medical marijuana treatments.
  • A partnership with Rapid Interactive Disability Management (“RIDM”) was formed resulting in a new revenue stream through the completion of Independent Medical Evaluations (“IMEs”) as required in medical cannabis cases by Canadian employers and insurance providers.
  • Canabo has trained 65 physicians in its proprietary physician training program, up from 30 physicians at the time of listing. In addition, 26 Continuing Medical Education (“CME”) sessions have been held, with over 700 referring physicians attending.  

 Clinic Locations

“During the month of November we saw approximately 800 new patients, and six months later, we are seeing approximately 1,200 new patients per month.  Our growth rate is driven by new clinic openings as well as partner clinic growth,” stated Smith.  “The partner clinic model provides great advantages in supporting Canabo’s aggressive expansion strategy,” added Smith. “Capital outlay is lower for each new partner clinic, and these clinics have an existing patient roster which allows us to reach new patients requiring care sooner.”

 Financing, Cash and Market Activity

“In December, an $8.4 million financing was completed by Aphria Inc. at $1.40 per share. As a result, Canabo is well-funded and on target to achieve a cash flow positive run-rate by year’s end.” stated Smith. At present, the Company has cash on hand of $8.5 million, or approximately $0.22 cents per share.  Canabo will not require additional equity financing for the foreseeable future.

The $8.4 million investment was an equity position only and did not result in a controlling position, or include any guarantee of Canabo patients to Aphria.

In response to numerous enquiries regarding the decline in Canabo’s share price in recent weeks, management confirms that there is no fundamental reason for this decline.   Canabo’s business is strong and growing, with volumes currently at record levels. 

 New Revenue Stream – IME

Smith noted, “Through our partnership with RIDM, we are seeing encouraging growth in our Independent Medical Evaluations revenue stream. Our reputation for the highest quality of medical practice and our conservative, thoughtful approach to prescribing medical marijuana is positioning Canabo as a preferred partner within the insurance industry to complete IMEs.  Canabo provides a fee for service for IMEs.  This service offering is projected to grow month over month for the foreseeable future as we are currently in discussions to become the preferred provider of medical marijuana IMEs for multiple clients.” 

 New Revenue Opportunities – Research

“At Canabo, we believe our core advantage relates to research and big data revenue,” emphasized Smith. “Our benzodiazepine study, as reported April 7, 2017, was well received and demonstrated that our physician and clinic network is ideally suited to complete meaningful medical research on cannabinoid treatments. Terra Life Sciences recognized this advantage, and we are working with them to develop new cannabinoid treatments that one day may result in broader acceptance of medical marijuana treatments within the medical community.   Canabo is making important advancements by generating compelling research, while securing agreements with our partners which will allow for future licensing revenues for products we assist in developing, representing a significant Blue Sky opportunity,”  said Smith.

“We expect analytics and contract research will be a significant revenue source in the near term.  Our current database has over 2 million data points and is growing monthly.  To our knowledge, Canabo hosts the largest medical marijuana database in existence.  Canabo is a partner of choice for industry participants pursuing new treatment products, setting human resources policies, accessing data to support new regulation and analyzing or comparing treatment costs. In addition, physicians and experts in medical marijuana treatments often seek data on patient feedback or patient reactions pertaining to various treatment protocols.”

 Near-Term Opportunities

“The medical marijuana industry is evolving and developing fast, and we see ourselves at the forefront,” added Smith. “Our position as a market leader in medical marijuana is well established.   We expect to be in a position to announce new research projects over the next 6 to 12 months, and we expect our patients and database to continue to grow. Our reputation as the best-in-market participant in Canada is now being recognized outside the country.  Canabo is in discussions with medical operators or regulators in other countries. Our training, protocols and research collection methods may serve as a valuable ‘jump-start’ for groups in other countries adopting medical marijuana treatments.”

 About Canabo

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis.  Established in 2014, Canabo now has 16 clinics across Canada, with several additional locations planned to open in 2017.  Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

 Forward Looking Statements

 Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks. 

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information, please contact:

Ms. Bianca Müller

Telephone: +1-902-334-1700
Email:  media@cmclinic.ca

www.canabocorp.com

Canabo Signs Collaborative Agreement to Jointly Develop Specifically Targeted Cannabinoid Treatments with Terra Life Sciences Inc.
May 15th, 2017

May 15, 2017 – Vancouver, British Columbia – Canabo Medical Inc. (TSX-V: CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to announce it has entered into a collaborative agreement (“Agreement”) with Terra Life Sciences Inc. (“Terra Life”) of Calgary, Alberta to jointly work on the R&D and clinical application of cannabinoid-based treatments targeted to specific conditions. The intended outcome of the agreement will be to develop new cannabinoid-based formulations to target specific medical conditions and illnesses such as chronic pain or anxiety. In addition, the agreement specifies both parties will conduct joint medical research and testing, and share future revenues from any new medical formulations and IP developed.

Terra Life Sciences is a holding company of a subsidiary operating as Olds SoftGels Inc. The Terra Life Sciences group owns and operates two pharma-grade facilities with capabilities to manufacture pharmaceuticals, over the counter (“OTC”) and premium grade nutraceuticals. Terra Life currently manufactures over 100 different products and has a manufacturing capacity of over 2.5 billion softgels per year, with access to an R&D department that includes 8 PhDs on staff. These facilities are licensed by Health Canada and are fully GMP compliant.

Key aspects of the Agreement include both companies working jointly to identify, develop and conduct medical research on new cannabinoid formulations designed to assist patients with specific conditions such as pain management and anxiety. The Agreement also provides for revenue sharing on any licensing revenues resulting from any newly developed products. The Agreement covers the following key stages.

Identifying opportunities for condition treatments – review of Canabo’s patient observational data to identify conditions and illnesses that show promise for successful replacement of existing therapies.

R&D – chemical, genetic and extraction lab work lead by Terra Life to develop cannabinoid formulations uniquely targeted to specific conditions with feedback and input from the Canabo physician network.

QA/QC production and dosage control – Terra Life will oversee the processing of targeted cannabinoid plants, cannabis oils, active ingredients and manage quality assurance testing and processing into delivery mechanisms, such as softgel capsules, to provide precise dosage control.

Observational data collection – utilizing Canabo’s network of physicians and patients, Canabo will observe patient response and treatment efficacy for both primary conditions and side effects and where appropriate, Canabo physicians will publish the observational data.

Product formulation adjustment – based on observational research data, additional R&D work on cannabis formulation development will be led by Terra Life.

Clinical trial testing – jointly, and including participation from independent physicians and researchers, Canabo and Terra Life intend to conduct double- blind, placebo controlled clinical trials pertaining to each newly developed cannabinoid formulation. It is anticipated all clinical trials will be physician peer-reviewed and published in medical journals.

Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “Today’s announcement represents a significant goal for Canabo, using best-practice R&D to target specific conditions, achieving high QA/QC and dosage control, and evidence based research. This future for cannabinoid treatments is precisely what patients and prescribing physicians want.”

Dr. Anil Jain, President and CEO of Terra Life Sciences Inc. added, “The medical cannabis industry is in its infancy. To grow beyond the current anecdotal practices the industry needs innovative science, controlled production and evidence-based research. This collaboration will elevate the industry with Canabo and Terra Life Sciences at the forefront.”

For further information, please contact:

Ms. Bianca Muller, Media Manager Telephone: +1-902-334-1700

Email: media@cmclinic.ca www.canabocorp.com

Miriam Mitchell-Banks, General Manager, Supply Chain

Telephone: +1-403-630-0898

email: miriam@terralifesciences.com

www.terralifesciences.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Canabo Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s most respected and largest referral-only clinics for medical cannabis. Since beginning operations in 2014, Canabo now has clinic locations in Toronto, Barrie, St. Catharine’s, Burlington, Stoney Creek, Ottawa, Hamilton, Halifax, St. John’s, Moncton, Kingston, Edmonton, Calgary and Chilliwack.

About Terra Life Sciences Terra Life Sciences is a holding company of a subsidiary operating as Olds SoftGels Inc. The Terra Life Sciences Group (“The Group”) owns and operates two pharma-grade facilities with capabilities to manufacture highly potent pharmaceuticals, Over the Counter (“OTC”) and premium grade nutraceuticals, for both domestic and international markets. One of these facilities has been operating for more than thirty years. These facilities are licensed by Health Canada and fully GMP compliant.

The Group is the process of securing its ACMPR license to enable the extraction of Active Pharmaceutical Ingredients from Cannabis and to manufacture and sell pharma-grade doses in various delivery systems. The Group offers excellence in manufacturing doses in various delivery systems such as softgels, liquids, topical, sprays and liposomes, with capabilities for quick release, sustained release and targeted release of medicine. The Group is focused on scientific research and collaboration, and has plans to participate in clinical trials to fully explore the potential of cannabis for patient health, and to provide evidence-based products for the comfort of health practitioners.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting

potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Canabo Announces New Partnership Agreement with Aviva Medical Securing Additional Clinics and access to 15,000 New Patients
May 4th, 2017

May 4, 2017 – Vancouver, BC – Canabo Medical Inc. (TSXV:CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) announces it has entered into a letter of intent (“LOI”) with Aviva Medical Ltd. (“Aviva Medical”, formerly, Medica One Ltd.) to enter into a share exchange agreement (“SEA”).  The SEA will replace a previous agreement that covered the operations of CMClinics in Hamilton, Stoney Creek and Burlington.  Aviva Medical will operate five existing medical marijuana CMClinics in Ontario.  Aviva Medical currently operates clinics in Hamilton, Stoney Creek, Burlington, and will assume operations of Canabo’s Barrie and St. Catharine’s clinics.  It is proposed that Aviva Medical will open four new CMClinics Oakville, Niagara Falls, Peterborough and Etobicoke.  Aviva Medical will operate a total of nine Canabo CMClinics in Ontario.

Patients at all new and existing Aviva Medical operated CMClinics will be seen under Canabo’s trained procedures, protocols, standards and research programs.  All patients will also be enrolled in Canabo’s medical data collection program.

Dr. Neil Smith, Executive Chairman of Canabo, stated “Aviva Medical is a great clinic operator. We are tremendously happy that this agreement will expand our clinic base within Ontario and quickly give us access to a further 15,000 patients.”

Marcia Villafranca, President of Aviva Medical, added “We are pleased to move forward with Canabo’s expertise in the field of medical cannabis research and treatments. Our physicians are happy to join their research team and contribute to a wider acceptance in the medical community of medical marijuana treatments.”

Operational services will be provided by Aviva Medical under the terms of the SEA with Canabo. Pursuant to the SEA, Canabo will acquire all issued and outstanding shares of an Ontario corporation (“NewCo”) to be incorporated by Aviva Medical for the operations of the CMClinics.  Aviva Medical will exchange all NewCo shares for common shares of Canabo Medical Inc.  The number of exchanged Canabo shares, up to a maximum of 1,742,160 common shares, will be calculated under a formula at closing depending on the number of new patients, based on the 5-day volume weighted average price of $0.6888 per share, subject to a minimum of 10,000 new patients being achieved within the next three years.  Any Canabo shares issued under the SEA will be subject to a 12-month voluntary pooling agreement.  The agreement is subject to both parties maintaining certain performance and quality assurance provisions, the execution of the SEA and TSX Venture Exchange approval.

 

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has 16 clinics across Canada as well as partnership clinics with Aviva Medical and Peak Medical Group, with several additional locations set to open in 2017.

Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. 

 

For further information, please contact:

Bianca Muller
Telephone:+1-902-334-1700
Email: bmuller@canabocorp.com

http://www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.  

The forward-looking statements in this press release are also based on a number of assumptions that may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor. 

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

 

Canabo Opens Clinic in Kelowna, BC and Provides Update on Peak Medical Group
April 19th, 2017

April 19, 2017 – Kelowna, BC – Canabo Medical Inc. (TSX-V:CMM) (OTCQB:CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its 16th clinic in Kelowna, British Columbia. The Kelowna clinic is located in the Sterling Centre at 3975 Lakeshore Road, and will be led by Dr. Chemanthi Kalen.

Canabo is also pleased to provide an update on its growth with Peak Medical Group (“Peak Medical”) who operates partner clinics for Canabo throughout Alberta. Peak Medical has recently opened a new, second location in Edmonton in order to accommodate high patient demand.

Dr. Neil Smith, Executive Chairman stated, “Kelowna marks the 6th clinic opening for Canabo in 2017 and demonstrates we are continuing to execute on our aggressive clinic roll out schedule.  We are also pleased with our patient growth in Alberta through our partner Peak Medical”.

About Canabo Medical Inc.

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has 16 clinics across Canada with several additional locations set to open in 2017.

Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

 

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions that may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information, please contact:
Ms. Madeline Whittaker
Telephone:  +1(902) 334-1700
Email: media@cmclinic.ca
www.canabocorp.com

Contact Us

Phone: 1-888-282-7763
Fax: 1-844-320-9652

Our Patient Care Centre is open Monday through Friday from 7:30am to 7:00pm (EST) 

Toronto 
1 Eglinton Ave. E., Suite 407
Toronto, ON  

Barrie 
11 Lakeside Terrace, 2nd Floor
Barrie, ON  

Ottawa 
1385 Bank St., Suite 305
Ottawa, ON  

Stoney Creek
35 Upper Centennial Pkwy., 2nd Floor
Stoney Creek, ON  

Hamilton
414 Victoria Ave., Suite M8
Hamilton, ON  

Burlington
2951 Walkers Line, 3rd Floor, Suite 305
Burlington, ON  

London
130 Thompson Road
London, ON  

Kingston
725 Arlington Park Place
Kingston, ON  

St Catharines 
Niagara Health Center
180 Vine Street South, Suite 306
St Catherines, ON  

Moncton/Sackville
112 Main Street, Unit D
Sackville, NB

Halifax  
5991 Spring Garden Rd., Suite 440
Halifax, NS

Wolfville
2 – 4 Little Road,
Wolfville, NS

St. John’s
8-10 Rowan St., Suite 206
St. John’s, NL  

Edmonton
11010-101 St. NW, Suite 608
Edmonton, AB 

Calgary
70 Country Hills Landing NW, Suite 103
Calgary, AB   

Chilliwack
9181 Main Street, Suite 214
Chilliwack, BC  

Kelowna
3975 Lakeshore Road, Suite #201
Kelowna, BC